Published: October 2004
Pages: 57
Published by: HTStec

Table of Contents

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.

Highlights of this Report:

• This market report summarizes the results of a comprehensive global Pharma and Biotech and Research web-based survey on label free detection trends. In particular, it looks at the current use of label free detection; what technologies might be displaced by label free in the future; the requirements for a new label free detection system; and the market potential for label free detection in the Pharma primary screening segment.
• The survey collected 84 responses (78 complete and 6 partially filled out) from 40 different Pharma and Biotech companies and 18 Academic Research Institutes.
• Responses from Pharma and Biotech were split geographically 56% North America and 44% Europe. Responses from Research were split geographically 85% Europe,10% North America and 5% ROW.
• Survey respondents were drawn from 38 Large Pharma, 26 Small Pharma/Biotechs, and 20 Research Institutes/University Labs.
• Survey respondents represented 39 assay development and primary screening (HTS) labs, 8 secondary screening labs, 4 hits-to-leads (lead optimization) labs, 4 therapeutic area labs, 2 compound profiling labs, 2 leads-to-candidate labs, 5 other Pharma and Biotech lab functions and 20 academic research labs.
• Survey results were expressed as an average of all survey respondents. In addition, the data was fully reanalyzed after sub-division into the following survey groups: 1) Pharma and Biotech - All Respondents; 2) Pharma and Biotech - Label Free Users Only; 3) Pharma and Biotech - Label Free Non-Users; 4) Research – All Respondents; and 5) Research – Label Free Users Only.
• The majority (45%) of respondents perceived label free as ‘a promising analytical tool that needs to mature’.
• 63% of respondents surveyed were currently using label free and had a fair to excellent understanding of it capabilities.
• The greatest current use of label free detection among respondents was kinetic (on and off rate) analysis, closely followed by affinity analysis.
• Receptor-ligand and drug-target were the most investigated molecular interactions studied by respondents.
• Respondents’ first choice among existing technologies to be displaced by label free was split between radio-active (31%) and ELISA (24%) assays. In addition, a similar proportion (29%) of respondents don’t see label free replacing any of their existing technologies. Further details on the specific assay detection technologies respondents wish to displace are given the report.
• All survey respondents were aware of surface plasmon resonance (SPR) and its use in label free detection. Respondent awareness of other types of label free detection, including emerging technologies, was less evident.

Purchase report >>